{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+solution&page=35",
    "query": {
      "intervention": "placebo solution",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 3139,
    "total_pages": 314,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+solution&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+solution&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T19:17:40.160Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04843761",
      "title": "ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Remdesivir",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Remdesivir Placebo",
          "type": "DRUG"
        },
        {
          "name": "Aviptadil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aviptadil Placebo",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 473,
      "start_date": "2021-04-20",
      "completion_date": "2022-11-20",
      "has_results": true,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-10-30T19:17:40.160Z",
      "location_count": 40,
      "location_summary": "Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04843761"
    },
    {
      "nct_id": "NCT02525718",
      "title": "Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 79 Years · Female only"
      },
      "enrollment_count": 47,
      "start_date": "2015-08",
      "completion_date": "2017-03",
      "has_results": true,
      "last_update_posted_date": "2019-08-14",
      "last_synced_at": "2026-10-30T19:17:40.160Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02525718"
    },
    {
      "nct_id": "NCT06812390",
      "title": "Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cirrhosis",
        "Ascites Hepatic"
      ],
      "interventions": [
        {
          "name": "Albumin infusion (25% albumin)",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anahita Rabiee MD MHS",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-02-28",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-10-30T19:17:40.160Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06812390"
    },
    {
      "nct_id": "NCT01257204",
      "title": "Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 196,
      "start_date": "2010-12",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2015-12-14",
      "last_synced_at": "2026-10-30T19:17:40.160Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257204"
    },
    {
      "nct_id": "NCT00793000",
      "title": "Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Tract Infections"
      ],
      "interventions": [
        {
          "name": "PF-04287881",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 80,
      "start_date": "2008-11",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2011-05-04",
      "last_synced_at": "2026-10-30T19:17:40.160Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00793000"
    },
    {
      "nct_id": "NCT03737851",
      "title": "A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis (MS)"
      ],
      "interventions": [
        {
          "name": "elezanumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 208,
      "start_date": "2018-12-11",
      "completion_date": "2021-09-09",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-10-30T19:17:40.160Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Hanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03737851"
    },
    {
      "nct_id": "NCT07531251",
      "title": "Clinical Trial in Patients With Barth Syndrome- 4TAZPower",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Barth Syndrome"
      ],
      "interventions": [
        {
          "name": "Elamipretide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stealth BioTherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "5 Years to 55 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2026-07-02",
      "completion_date": "2029-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-30T19:17:40.160Z",
      "location_count": 1,
      "location_summary": "Needham, Massachusetts",
      "locations": [
        {
          "city": "Needham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07531251"
    },
    {
      "nct_id": "NCT02228031",
      "title": "Oxytocin, Emotions and Mirror Neurons",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Social Cognition",
        "Expressed Emotion"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "MALE",
        "summary": "18 Years to 30 Years · Male only"
      },
      "enrollment_count": 44,
      "start_date": "2014-10",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-10-30T19:17:40.160Z",
      "location_count": 1,
      "location_summary": "College Park, Maryland",
      "locations": [
        {
          "city": "College Park",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02228031"
    },
    {
      "nct_id": "NCT00811395",
      "title": "Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for teriflunomide)",
          "type": "DRUG"
        },
        {
          "name": "Interferon-β [IFN-β]",
          "type": "DRUG"
        },
        {
          "name": "Glatiramer Acetate [GA]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 182,
      "start_date": "2007-10",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2012-12-31",
      "last_synced_at": "2026-10-30T19:17:40.160Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811395"
    },
    {
      "nct_id": "NCT00564629",
      "title": "Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fever"
      ],
      "interventions": [
        {
          "name": "Intravenous acetaminophen plus oral placebo",
          "type": "DRUG"
        },
        {
          "name": "Oral acetaminophen plus IV placebo",
          "type": "DRUG"
        },
        {
          "name": "Reference standard endotoxin (RSE)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "18 Years to 75 Years · Male only"
      },
      "enrollment_count": 105,
      "start_date": "2007-08",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-10-30T19:17:40.160Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00564629"
    }
  ]
}